In this study we aimed to look at the effects of opioid-receptor selective agonists and antagonists on insulin secretion in the pancreatic β-cell line RIN-5F. Cells were treated for 24 hours with 1μM of selective agonists (DAMGO for MOP, DPDPE for DOP, U50488 for KOP) in the presence or absence of 10μM of selective antagonists (CTOP for MOP, naltrindole for DOP, norBNI for KOP).
Introduction
Diabetes mellitus is a metabolic disease that is characterised by a disturbance in glucose and insulin homeostasis. Insulin is excreted centrally by the nervous system and locally by the pancreatic β-cells in response to plasma glucose levels and other endocrine signals Diabetes is clinically divided in two types: Type 1 (T1DM) results from failure of the pancreas' ability to produce enough insulin to regulate the body's metabolism, mainly due to an autoimmune degeneration of pancreatic β-cells 2 Patients with diabetes mellitus may develop different types of painful neuropathies. About 30% of diabetic patients experience neuropathic pain due to nerve injury induced by diabetes and about 20% of patients will develop chronic pain at some point during their life 9, 10 . Although opioids like morphine and fentanyl are considered ideal medications for medium-severe pain, their efficacy in diabetic neuropathy is as limited as in other types of neuropathic pain 11 .
Nevertheless, the combination of opioids with non-opioid drugs that are effective in neuropathic pain (such as α2 adrenoceptor agonists and serotonin/noradrenaline reuptake inhibitors) has proven to offer certain therapeutic advantages 12 , while it is being used in cases of diabetic neuropathies where first-line treatment with anticonvulsants or antidepressants was ineffective 11, 13, 14 .
Opium has been used for thousands of years due to its various therapeutic and recreational properties (i.e. analgesia, euphoria, drowsiness). However, it was only after the discovery of the three classical opioid receptor types (mu; MOP, delta; DOP, kappa; KOP) 15 and their endogenous ligands (endomorphins, enkephalins and dynorphins respectively) that we increased our understanding for the opioid system and made opioid drugs one of the few classes of compounds that have been studied for so long 16 . Opioid receptors are found in a wide variety of tissues, including the hypothalamicpituitary system, while their role and effect in endocrine regulation has been well-studied during the last decade 17, 18 . All opioid receptors (MOP and DOP primarily, KOP in less extend) have been shown to be expressed in the pancreas and liver, while endogenous opioid peptides and their receptors have been shown to be present in pancreatic α-and β-cells [19] [20] [21] .
Nevertheless, the first published work on the identification of endogenous opioids in the pancreas 22 gave rise to studies that focused on the ambiguous mechanisms involved in the endogenous opioid-mediated glucose and insulin homeostasis [23] [24] [25] . Green et al 24 first showed that morphine and met-enkephalin were able to stimulate glucose-induced insulin release in isolated pancreatic isles, an effect that was observed to develop rapidly, representing the first phase of pancreatic insulin release and which could be blocked by naloxone pre-treatment and therefore, showing an opioid-receptor mediated effect. A number of studies that followed confirmed the results of Green et al either directly [26] [27] [28] 24, 26, 27; 28, 29, 32, 33 , while others have shown the opposite inhibitory effect [34] [35] [36] [37] [38] [39] .
A major hypothesis for this inconsistency is based on the different methodologies employed and the different models used in detecting insulin levels 1, 40 . The insulin signaling system is autoregulated through different homeostatic mechanisms that involve glucose and glucagon secretion (among others). It is therefore most likely that observations of insulin secretion using high-complexity models (e.g. Here we report the effect of different opioid receptor-selective ligands, agonists and antagonists, to glucose-induced insulin release in a rat pancreatic cell line. In this study, we are using the wellcharacterised rat pancreatic β-cell line, RIN-5F, which releases insulin in glucose-containing media 41 .
Methods

Materials
The pancreatic β-cell line (RIN-5F) was purchased from the hydrochloride (U50488) was purchased by Tocris Bioscience.
Naltrindole hydrochloride and the trypan blue solution (0.4%,100 ml/bottle) were purchased by Sigma-Aldrich. All other reagents used were purchased with the highest quality available.
Cell culture and maintenance
Cells were cultured and maintained in a similar way as previously described 42 . Briefly, RIN-5F rat pancreatic β-cells were grown in penicillin, and 100 mg ml -1 streptomycin. Stock cultures were grown at 37 C with 5% CO2 95% humidity and were subcultured twice a week as required using phosphate buffered saline and trypsin/0.5mM EDTA. Cells were used for experiments as they approached
confluence. An appropriate volume of cells was seeded in the wells of a 96-well plate, in the presence or absence of drugs in a total volume of 200μl and were incubated for 24 hours. Prior to the main experiment, the cell number-dependent basal insulin secretion levels of RIN-5F cells (1x10 4 , 2x10 4 and 4x10 4 cells/well) were determined.
Drug treatment
Cells were treated with a selective opioid-receptor agonist at 1μM to determine the effect of these ligands on insulin secretion. Cells that were not treated with any compound were used as a negative control.
Immunoassay for insulin detection
An enzyme-based immunoassay (sandwich ELISA) was used to The enzyme activity was measured by spectrophotometry at 450 nm, corrected from the absorbance of 590nm, after the acidification of formed products with 0.3M HCL. Since the increase in absorbance is directly proportional to the amount of captured insulin in the samples, the latter was derived by interpolation from a reference curve generated within each performed assay using reference standards of known concentrations of rat insulin. The dose-response curve produced by the internal standards was fitted to a sigmoidal 4-parameter logistic equation according to the manufacturer's instructions by plotting the corrected absorbance at 450nm minus 590nm, against the concentration of rat insulin standards.
Viability assay
A Trypan blue exclusion assay was used to determine the viability of 
Data analysis
Concentration-response curves were analysed by linear regression or by a 4-parameter sigmoidal fit, as appropriate. GraphPad Prism V6.0 software (San Diego, CA, USA) was used for statistical analysis. Students t-test and analysis of variance (ANOVA) with multiple comparison testing were used as required and as described in the table and figure legends (minimum significance set at p<0.05).
Data is presented as mean ± SD from (n) number of experiments as indicated in the respective figure or table legends.
Optimization of insulin detection
RIN-5F cells physiologically secrete insulin when incubated in an appropriate glucose-contained growth medium. Since the amount of secreted insulin/well is dependent on cell numbers, we first optimized cell numbers per well for a 96 well format to obtain absorbance values that fall within the range of values of the standard curve.
Three different concentrations were used (1x10 4 , 2x10 4 and 4x10 4 cells/well) with five parallel wells per group.
Known amounts of insulin (0, 0.5, 1, 2, 5, 10 ng/ml) were used in triplicates as internal standards to produce a standard curve ( Figure   1 ), which was initially fitted using linear regression analysis (R 2 = 0.9898), confirming the linearity of the internal standards ( Figure 1A ).
Subsequently, the same data was fitted more efficiently to a 
Total secreted insulin after opioid treatment
After determining the optimal cell density numbers per well, we measured insulin secretion of cells seeded and treated with test
compounds. An internal standard curve was generated within this assay and analyzed using both analysis methods (linear regression and the 4-parameter sigmoidal logistic equation; Figure 2A , B). In agreement with the previous data, the sigmoidal standard curve provided a better fit compared to a linear fit and was therefore used to interpolate the absorbance values produced by the samples.
After taking into account the dilution factor used to dilute the samples 
Secreted insulin / cell numbers at endpoint
Since the test compounds can potentially affect cellular viability and proliferative capacity, which is likely to affect the extent of secreted insulin, it is important to account for these potential effects when evaluating the stimulatory or inhibitory effects of drug-induced insulin secretion. We therefore, measured cellular viability using trypan-blue (TB) exclusion, immediately after the collection of the supernatant.
Since the assay provides information on the number of dead and Finally, since naltrindole completely killed the treated cells over a period of 24 hours, the ratio of insulin release/cell number could not be determined. However, the total insulin reduction in the naltrindoletreatment shows that naltrindole's toxicity is so rapid that it inhibited the basal glucose-induced insulin excretion. Also, the increase of insulin seen with DPDPE was significantly abolished by naltrindole co-treatment (3.02 0.48 ng/ml/10 3 cells; a 51.6% decrease) due to naltrindole's toxicity, but it was not zero. DPDPE's concentration in the co-treatment group was 10% of that of naltrindole and was still able to contain some of naltrindole's toxicity, insinuating a competitive behavior for both actions (DPDPE's insulin stimulation and naltrindole's toxicity) which most likely is mediated through the DOP receptor.
Discussion
Opioids represent an important drug class in diabetic pharmacotherapy due to their role in diabetic neuropathy and their complex and under-explored endocrine effects. Although opioids are not considered very effective as a stand-alone treatment for diabetic neuropathic pain, their strong analgesic effect offers a potential coadministration solution to drug-resistant and persistent neuropathic pain 44 . In addition, the remarkable wide range of tissues that express the classical opioid receptors constitutes the basis of their non-analgesic side effects, some of which are currently explored for conditions other than pain [45] [46] [47] . The expression of opioid receptors in pancreas and liver 47 initiated early studies to perceive the role of endogenous opioids in processes associated with the endocrine and autocrine system 49 , such as glucose homeostasis 50 and insulin show a stimulatory effect of opioids as described in the introduction section above.
Similarly to Qian et al 38 who used an MTT viability assay to assess whether opioid effect cellular toxicity of the opioid concentrations used, we used the TB viability assay to account for the potentially different effects of the different opioids used.
In addition, we have observed that the MOP-selective antagonist CTOP also significantly increased insulin secretion in our cells, which clearly shows that a MOP receptor antagonist can also increase insulin secretion similarly to MOP receptor agonist like DAMGO. This result insinuates that the effect of increased insulin secretion is either mediated through a non-opioid receptor mechanism or through a Gprotein-activation independent mechanism. However, the reduced effect on insulin release by the co-treatment of DAMGO and CTOP compared to individual treatment presents a case of antisynergism which insinuates an opioid-receptor mediated mechanism, although further investigation is needed to draw solid conclusions.
In this manuscript we also show the insignificant contribution of the Our data suggest that the KOP receptor targeted ligands U50488
and norBNI did not produce a significant insulin release compared to control. These two ligands are structurally very different from the rest of the opioids tested since they are not peptides. In addition, although it is questionable whether KOP receptors are expressed in pancreatic islets, higher concentrations of these ligands need to be tested in the future to check whether there is an effect on insulin secretion. However, in a recent study by Shang et al 55 , treatment of STZ-mice with U50488 reduced hyperglycemia but did not affect plasma insulin levels, which shows that KOP receptors may play a role in glucose-homeostasis rather than insulin secretion per se.
Conclusion
Our study furnishes evidence of the opioid-induced increase of insulin secretion, by receptor selective agonists and antagonists, which implies that the role of opioid receptors in insulin secretion in β-cells is more complicated than G-protein dependent. Moreover, investigation into the molecular pathways that are involved downstream of the opioid receptor after ligand binding is needed to clarify the role of opioid receptors on insulin secretion.
Understanding these pathways may provide an insight in novel pancreatic mechanisms of insulin secretion and the identification of novel drug targets for diabetes.
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